Vincerx Pharma Terminates Reverse Merger Deal With Oqory

Dow Jones

Mar 01, 2025

By Stephen Nakrosis

Vincerx Pharma has terminated a reverse merger agreement with Oqory and its parent company Vivasor.

The company said Friday it terminated an approved term sheet signed as part of deal after Oqory ended an exclusivity provision. Vincerx said it will explore strategic options.

The agreement would have seen Oqory merge with Vincerx, resulting in a combined company 95% owned by Oroqy equity holders. The deal would also have seen Oqory-designated investors provide $1.5 million of interim financing to Vincerx.

The company said it will review strategic alternatives, including out-licensing, merger and acquisition opportunities, and winding down operations, among other options. Vincerx said it had about $3.9 million in cash as of Feb. 26, and expects to have enough cash to operate late into the second quarter of this year.

Shares of Vincerx closed the market session down 13% at $1.09. The stock plunged 98% in the past year.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

February 28, 2025 16:55 ET (21:55 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2516071793"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2516071793\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2516071793?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-01 05:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2516071793","market":"us","top_or_hot":-1,"title":"Vincerx Pharma Terminates Reverse Merger Deal With Oqory","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  Vincerx Pharma has terminated a reverse merger agreement with Oqory and its parent company Vivasor. \n</p>\n<p>\n  The company said Friday it terminated an approved term sheet signed as part of deal after Oqory ended an exclusivity provision. Vincerx said it will explore strategic options. \n</p>\n<p>\n  The agreement would have seen Oqory merge with Vincerx, resulting in a combined company 95% owned by Oroqy equity holders. The deal would also have seen Oqory-designated investors provide $1.5 million of interim financing to Vincerx. \n</p>\n<p>\n  The company said it will review strategic alternatives, including out-licensing, merger and acquisition opportunities, and winding down operations, among other options. Vincerx said it had about $3.9 million in cash as of Feb. 26, and expects to have enough cash to operate late into the second quarter of this year. \n</p>\n<p>\n  Shares of Vincerx closed the market session down 13% at $1.09. The stock plunged 98% in the past year. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 28, 2025 16:55 ET (21:55 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vincerx Pharma Terminates Reverse Merger Deal With Oqory</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVincerx Pharma Terminates Reverse Merger Deal With Oqory\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-03-01 05:55</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  Vincerx Pharma has terminated a reverse merger agreement with Oqory and its parent company Vivasor. \n</p>\n<p>\n  The company said Friday it terminated an approved term sheet signed as part of deal after Oqory ended an exclusivity provision. Vincerx said it will explore strategic options. \n</p>\n<p>\n  The agreement would have seen Oqory merge with Vincerx, resulting in a combined company 95% owned by Oroqy equity holders. The deal would also have seen Oqory-designated investors provide $1.5 million of interim financing to Vincerx. \n</p>\n<p>\n  The company said it will review strategic alternatives, including out-licensing, merger and acquisition opportunities, and winding down operations, among other options. Vincerx said it had about $3.9 million in cash as of Feb. 26, and expects to have enough cash to operate late into the second quarter of this year. \n</p>\n<p>\n  Shares of Vincerx closed the market session down 13% at $1.09. The stock plunged 98% in the past year. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 28, 2025 16:55 ET (21:55 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2516071793","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2516071793","pubTimestamp":1740779700,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Vincerx Pharma has terminated a reverse merger agreement with Oqory and its parent company Vivasor.The company said Friday it terminated an approved term sheet signed as part of deal after Oqory ended an exclusivity provision. Vincerx said it will explore strategic options.The agreement would have seen Oqory merge with Vincerx, resulting in a combined company 95% owned by Oroqy equity holders. The deal would also have seen Oqory-designated investors provide $1.5 million of interim financing to Vincerx.The company said it will review strategic alternatives, including out-licensing, merger and acquisition opportunities, and winding down operations, among other options. Vincerx said it had about $3.9 million in cash as of Feb. 26, and expects to have enough cash to operate late into the second quarter of this year.Shares of Vincerx closed the market session down 13% at $1.09. The stock plunged 98% in the past year.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","VINC":"Vincera Pharma, Inc."},"translate_title":"Vincerx Pharma终止与Oqory的反向合并交易","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VINC":0.9},"content_text":"By Stephen Nakrosis \n\n\n \n\n\n  Vincerx Pharma has terminated a reverse merger agreement with Oqory and its parent company Vivasor. \n\n\n  The company said Friday it terminated an approved term sheet signed as part of deal after Oqory ended an exclusivity provision. Vincerx said it will explore strategic options. \n\n\n  The agreement would have seen Oqory merge with Vincerx, resulting in a combined company 95% owned by Oroqy equity holders. The deal would also have seen Oqory-designated investors provide $1.5 million of interim financing to Vincerx. \n\n\n  The company said it will review strategic alternatives, including out-licensing, merger and acquisition opportunities, and winding down operations, among other options. Vincerx said it had about $3.9 million in cash as of Feb. 26, and expects to have enough cash to operate late into the second quarter of this year. \n\n\n  Shares of Vincerx closed the market session down 13% at $1.09. The stock plunged 98% in the past year. \n\n\n \n\n\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 28, 2025 16:55 ET (21:55 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"corporation,merge","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}